



Prevention of SARS-CoV-2 Infection and COVID-19: Safety, Immunogenicity and Effectiveness of Available Vaccines

Guest Editor:

Prof. Dr. Paolo Durando

1. Department of Health Sciences, University of Genoa, 16132 Genoa, Italy
2. Occupational Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy

Deadline for manuscript submissions:

closed (31 March 2024)

Message from the Guest Editor

The COVID-19 crisis is the greatest global challenge faced by the world in modern times. Vaccines represent a key preventive measure in the fight against infectious diseases, effectively reducing the morbidity and mortality caused by a specific pathogen among a susceptible population; however, unfortunately, the global burden of COVID-19 remains high, and evidence on the immunogenicity, safety and effectiveness of the current vaccines is still fundamental to guide further decisions on the ongoing immunization programmes. Clinical trial results can be influenced by various study biases; therefore, it is crucial to estimate these endpoints in real-world settings. In this Special Issue, we aim to gather high-quality evidence on the immunogenicity, safety and effectiveness of the currently available COVID-19 vaccines in different study populations. This will provide an evidence-based platform that will be extremely useful for the development of more accurate and effective public health strategies for COVID-19.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com